{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:17:25Z","timestamp":1648793845431},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00393-011-0900-9","type":"journal-article","created":{"date-parts":[[2012,2,27]],"date-time":"2012-02-27T15:25:38Z","timestamp":1330356338000},"page":"101-107","source":"Crossref","is-referenced-by-count":1,"title":["Off-Label-Therapie aus der Perspektive des MDK"],"prefix":"10.1007","volume":"71","author":[{"given":"L.","family":"Grell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,29]]},"reference":[{"key":"900_CR1","unstructured":"Arbeitsgemeinschaft Gyn\u00e4kologischer Onkologen (2011) Diagnostik und Therapie prim\u00e4erer und metastasierter Mammakarzinome: Chemotherapie bei metastasiertem Mammakarzinom; Guidelines Breast Version 2011.1D. http:\/\/www.ago-online.de\/_download\/unprotected\/g_mamma_11_1_0_d_20_cytotoxic_therapy_metastatic_bc.pdf. Zugegriffen: 4. Okt 2011"},{"key":"900_CR2","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2011) Die Expertengruppen Off-Label \u2013 Anwendung von Arzneimitteln au\u00dferhalb des zugelassenen Indikationsbereichs. http:\/\/www.bfarm.de\/DE\/Arzneimittel\/3_nachDerZulassung\/offLabel\/offlabel-node.html. Zugegriffen: 26. Sept 2011"},{"key":"900_CR3","unstructured":"Bundessozialgericht (2002) Urteil vom 19.03.2002, Az.: B 1 KR 37\/00 R"},{"key":"900_CR4","unstructured":"Bundessozialgericht (2004) Urteil vom 19.10.2004, Az.: B 1 KR 27\/02 R"},{"key":"900_CR5","unstructured":"Bundessozialgericht (2006) Urteil vom 04.04.2006, Az.: B 1 KR 7\/05 R"},{"key":"900_CR6","unstructured":"Bundessozialgericht (2006) Beschluss vom 31.05.2006, Az.: B 6 KA 53\/05 B"},{"key":"900_CR7","unstructured":"Bundessozialgericht (2006) Urteil vom 26.09.2006, Az.: B 1 KR 1\/06 R"},{"key":"900_CR8","unstructured":"Bundessozialgericht (2006) Urteil vom 14.12.2006, Az.: B 1 KR 8\/06 R"},{"key":"900_CR9","unstructured":"Bundessozialgericht (2007) Urteil vom 27.03.2007, Az.: B 1 KR 17\/06 R"},{"key":"900_CR10","unstructured":"Bundessozialgericht (2009) Urteil vom 30.06.2009, Az.: B 1 KR 5\/09 R"},{"key":"900_CR11","unstructured":"Bundesverfassungsgericht (2005) Beschluss vom 06.12.2005, Az.: 1 BvR 347\/98"},{"key":"900_CR12","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","volume":"289","author":"Chlebowski","year":"2003","unstructured":"Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289:3243\u20133253","journal-title":"JAMA"},{"key":"900_CR13","unstructured":"Department of Justice (2004) Warner-Lambert to pay $430\u00a0Mio to resolve criminal & civil health care liability relating to off-label promotion. http:\/\/www.justice.gov\/opa\/pr\/2004\/May\/04_civ_322.htm. Zugegriffen: 4. Okt 2011"},{"key":"900_CR14","unstructured":"Department of Justice (2009) Eli Lilly and Company agrees to pay $1.415 billion to resolve allegations of off-label promotion of Zyprexa: $515\u00a0Mio criminal fine is largest individual corporate criminal fine in history; civil settlement up to $800\u00a0Mio. http:\/\/www.justice.gov\/opa\/pr\/2009\/January\/09-civ-038.html. Zugegriffen: 4. Okt 2011"},{"key":"900_CR15","unstructured":"Department of Justice (2009) Justice Department announces largest health care fraud settlement in its history: Pfizer to pay $2.3 billion for fraudulent marketing. http:\/\/www.justice.gov\/opa\/pr\/2009\/September\/09-civ-900.html. Zugegriffen: 4. Okt 2011"},{"key":"900_CR16","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1371\/journal.pmed.0050210","volume":"5","author":"Fugh-Berman","year":"2008","unstructured":"Fugh-Berman A, Melnick D (2008) Off-label promotion, on-target sales. PLoS Med 5:e210","journal-title":"PLoS Med"},{"key":"900_CR17","unstructured":"Gemeinsamer Bundesausschuss (2011) Anlage VI zum Abschnitt K der Arzneimittel-Richtlinie: Verordnungsf\u00e4higkeit von zugelassenen Arzneimitteln in nicht zugelassenen Anwendungsgebieten (sog. Off-Label-Use). http:\/\/www.g-ba.de\/informationen\/richtlinien\/anlage\/zur-richtlinie\/3\/#15\/. Zugegriffen: 26. Sept 2011"},{"key":"900_CR18","unstructured":"Gemeinsamer Bundesausschuss (2011) Richtlinie des Gemeinsamen Bundesausschusses \u00fcber die Verordnung von Arzneimitteln in der vertrags\u00e4rztlichen Versorgung (Arzneimittel-Richtlinie\/AM-RL). http:\/\/www.g-ba.de\/informationen\/richtlinien\/zum-unterausschuss\/2\/#3\/. Zugegriffen: 26. Sept 2011"},{"key":"900_CR19","unstructured":"Gold R, Hartung H, Chan A, Kieseier B, Rieckmann P (2008) Diagnostik und Therapie der Multiplen Sklerose: AWMF-Leitlinien-Register Nr. 030\/050, Entwicklungsstufe: 1. http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/030-050_S1_Multiple_Sklerose__Diagnostik_und_Therapie_10-2008_10-2013.pdf. Zugegriffen: 5. Okt 2011"},{"key":"900_CR20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","volume":"299","author":"Heiss","year":"2008","unstructured":"Heiss G, Wallace R, Anderson GL et al (2008) Health risks and benefits 3\u00a0years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036\u20131045","journal-title":"JAMA"},{"key":"900_CR21","unstructured":"Lilly Deutschland GmbH (2004) Zyprexa, Zyprexa Velotab Schmelztablette und Zyprexa Pulver zur Injektion: Wichtige Information zu Olanzapin und zum Mortalit\u00e4ts- und Schlaganfallrisiko bei \u00e4lteren Patienten mit Demenz-assoziierter Psychose und\/oder Verhaltensst\u00f6rungen. http:\/\/www.akdae.de\/Arzneimittelsicherheit\/RHB\/Archiv\/2004\/85_20040308.pdf. Zugegriffen: 4. Okt 2011"},{"key":"900_CR22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","volume":"349","author":"Manson","year":"2003","unstructured":"Manson JE, Hsia J, Johnson KC et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523\u2013534","journal-title":"N Engl J Med"},{"key":"900_CR23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","volume":"297","author":"Rossouw","year":"2007","unstructured":"Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465\u20131477","journal-title":"JAMA"},{"key":"900_CR24","unstructured":"Sozialmedizinische Expertengruppe 6 \u201eArzneimittelversorgung\u201c der MDK-Gemeinschaft (2008) Off-Label-Use: Hinweise zur Begutachtung zur internen Verwendung durch die MDK-Gutachter. http:\/\/www.mdk-wl.de\/index.php?id=475. Zugegriffen: 26. Sept 2011"},{"key":"900_CR25","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.289.20.2673","volume":"289","author":"Wassertheil-Smoller","year":"2003","unstructured":"Wassertheil-Smoller S, Hendrix S, Limacher M et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women\u2019s Health Initiative: a randomized trial. JAMA 289:2673\u20132684","journal-title":"JAMA"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0900-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-011-0900-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0900-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:08Z","timestamp":1559061368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-011-0900-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1007\/s00393-011-0900-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}